Could Lilly’s Muvalaplin Be An Lp(a) Dark Horse?
The drug maker’s muvalaplin is only in Phase II – behind candidates from Amgen and Novartis – but an analyst said it has “mega-blockbuster” potential, assuming it has the right biological activity.
The drug maker’s muvalaplin is only in Phase II – behind candidates from Amgen and Novartis – but an analyst said it has “mega-blockbuster” potential, assuming it has the right biological activity.